STADA Arzneimittel Aktiengesellschaft
STADA Arzneimittel Aktiengesellschaft, commonly known as STADA, is a prominent player in the global pharmaceutical industry, headquartered in Bad Vilbel, Germany. Founded in 1895, the company has established a strong presence in Europe and beyond, focusing on the development, manufacturing, and marketing of generic and over-the-counter (OTC) products. STADA's core offerings include a diverse range of pharmaceuticals, particularly in the fields of pain management, dermatology, and respiratory health. The company is recognised for its commitment to quality and innovation, which has positioned it as a trusted provider in the healthcare sector. With a robust portfolio and a strategic focus on expanding its market reach, STADA continues to achieve significant milestones, reinforcing its status as a leader in the pharmaceutical landscape.
DitchCarbon Score
How does STADA Arzneimittel Aktiengesellschaft's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
STADA Arzneimittel Aktiengesellschaft's score of 58 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
STADA Arzneimittel Aktiengesellschaft's reported carbon emissions
In 2023, STADA Arzneimittel Aktiengesellschaft reported total carbon emissions of approximately 81827800 kg CO2e, comprising 40104500 kg CO2e from Scope 1 and 41723300 kg CO2e from Scope 2 emissions. This represents a significant reduction from 2021, when total emissions were about 114781000 kg CO2e. The company has set ambitious targets to reduce its absolute greenhouse gas emissions by 42% for both Scope 1 and Scope 2 by 2030, based on the 1.5°C global warming target. Notably, STADA has already achieved a 33.7% reduction in its Scope 1 emissions since 2020, alongside a similar reduction in Scope 2 emissions over the same period. The company is committed to transparency in its emissions reporting and has disclosed emissions data across all relevant scopes, including Scope 3, which accounted for approximately 672806000 kg CO2e in 2023. STADA's climate commitments align with industry standards, reflecting a proactive approach to sustainability within the pharmaceuticals sector. The company continues to work towards further reductions and improvements in its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 38,202,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 93,417,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
STADA Arzneimittel Aktiengesellschaft is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
